v3.26.1
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
At the market offering
Common Stock
Additional Paid-in Capital
At the market offering
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Accumulated Deficit
At the market offering
Total
Balance at beginning of period at Dec. 31, 2024   $ 1   $ 1,058,317 $ 97 $ (902,861)   $ 155,554
Balance at beginning of period (in shares) at Dec. 31, 2024   107,850,124            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock in connection with vesting of restricted stock units       (275)       (275)
Issuance of common stock in connection with vesting of restricted stock units (in shares)   415,405            
Unrealized gain/loss on marketable securities         337     337
Stock-based compensation expense       3,535       3,535
Net loss           (15,085)   (15,085)
Balance at end of period at Mar. 31, 2025   $ 1   1,061,577 434 (917,946)   144,066
Balance at end of period (in shares) at Mar. 31, 2025   108,265,529            
Balance at beginning of period at Dec. 31, 2024   $ 1   1,058,317 97 (902,861)   155,554
Balance at beginning of period (in shares) at Dec. 31, 2024   107,850,124            
Increase (Decrease) in Stockholders' Equity                
Net loss               (30,514)
Balance at end of period at Jun. 30, 2025   $ 1   1,064,631 482 (933,375)   131,739
Balance at end of period (in shares) at Jun. 30, 2025   108,328,794            
Balance at beginning of period at Mar. 31, 2025   $ 1   1,061,577 434 (917,946)   144,066
Balance at beginning of period (in shares) at Mar. 31, 2025   108,265,529            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock in connection with vesting of restricted stock units       (9)       (9)
Issuance of common stock in connection with vesting of restricted stock units (in shares)   63,265            
Unrealized gain/loss on marketable securities         48     48
Stock-based compensation expense       3,063       3,063
Net loss           (15,429)   (15,429)
Balance at end of period at Jun. 30, 2025   $ 1   1,064,631 482 (933,375)   131,739
Balance at end of period (in shares) at Jun. 30, 2025   108,328,794            
Balance at beginning of period at Dec. 31, 2025   $ 1   1,070,255 610 (967,784)   $ 103,082
Balance at beginning of period (in shares) at Dec. 31, 2025   120,499,433           120,499,433
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units       (99)       $ (99)
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   744,453            
Issuance of common stock under at-the-market sales agreement, net of offering costs of $1,884     $ 57,880       $ 57,880  
Issuance of common stock under at-the-market sales agreement, net of offering costs of $1,884 (In shares) 18,408,963              
Unrealized gain/loss on marketable securities         (588)     (588)
Stock-based compensation expense       3,198       3,198
Net loss           (19,824)   (19,824)
Balance at end of period at Mar. 31, 2026   $ 1   1,131,234 22 (987,608)   143,649
Balance at end of period (in shares) at Mar. 31, 2026   139,652,849            
Balance at beginning of period at Dec. 31, 2025   $ 1   1,070,255 610 (967,784)   $ 103,082
Balance at beginning of period (in shares) at Dec. 31, 2025   120,499,433           120,499,433
Increase (Decrease) in Stockholders' Equity                
Net loss               $ (41,329)
Balance at end of period at Jun. 30, 2026   $ 1   1,133,997 (304) (1,009,113)   $ 124,581
Balance at end of period (in shares) at Jun. 30, 2026   139,824,273           139,824,273
Balance at beginning of period at Mar. 31, 2026   $ 1   1,131,234 22 (987,608)   $ 143,649
Balance at beginning of period (in shares) at Mar. 31, 2026   139,652,849            
Increase (Decrease) in Stockholders' Equity                
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units       91       91
Issuance of common stock in connection with exercise of stock options and vesting of restricted stock units (in shares)   171,424            
Unrealized gain/loss on marketable securities         (326)     (326)
Stock-based compensation expense       2,672       2,672
Net loss           (21,505)   (21,505)
Balance at end of period at Jun. 30, 2026   $ 1   $ 1,133,997 $ (304) $ (1,009,113)   $ 124,581
Balance at end of period (in shares) at Jun. 30, 2026   139,824,273           139,824,273